ArticleDrug safety2023
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
Yamin Shu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this paperpooled itcites it